In their latest podcast, Optimum Stategic Communications dicuss the hot areas for investment in the shifting biotech market - including antibody-drug conjugates, smart radiotherapies, mRNA and immune-oncology.
Listen now!
Webinar will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds
BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, is hosting a webinar entitled “Uncooperative Drugs in In Vitro Transporter Research: Practical Approaches to Address Instability and Nonspecific Binding Challenges” at 11 am ET on September 20.
“In vitro drug transporter data are critical for understanding a compound’s drug-drug interaction potential. But if the compound being investigated is unstable, sticky…
Funds to support further development and commercialization of the Company’s INDUCE-seq DNA break mapping technology
Platform technology provides in situ off-target measurement in clinically relevant cells to accelerate the progression of cell and gene therapy programs
New investors include Illumina Ventures, Mérieux Equity Partners, and HERAN Partners
Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that…
Recognising that research and development and production of medicines requires a significant amount of energy, AstraZeneca recently shared an article on 'Powering emissions reductions with clean heat and renewable energy' explaining how they are working toward net zero goals with innovative partnerships.
Read the full article
"The addition of the 1.25 millionth structure to the CSD is a great achievement for the community. Being the world’s largest database of small-molecule organic and metal-organic crystal structure data, the CSD is used in over 70 countries by scientists and crystallographers working both in academia and in pharmaceutical companies. Each of the structures deposited by scientists from around the globe is curated by our expert scientific editors prior to entry in the database. It represents a fundamental platform to access structural data, to understand how molecules behave and interact in three…
After five years of leading LifeArc, Dr. Melanie Lee has informed the Board of her decision to step down as Chief Executive Officer.
Read the full press release.
We extend an invitation to explore our latest article titled "Powering Regional Growth: The Cambridge Cluster” penned by our CEO, Sunil Shah. The recent article which has been published by Intelligent Partnership delves into various facets of the biotech ecosystem, including insights on the golden triangle and tax-efficient investment strategies.
Should you find this content valuable, we would request you to share it with your professional network.
Important Notice - Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all…
Register now for our free workshop! Express your Tech: communicating your complex innovation
Thursday 5 October 2023 | 3:00pm to 6:30pm | St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS
You’ve spent years on research and product development, and now it’s time to take your product or service to market. But how do you sum it up in a sentence that excites investors? How do you put yourself in your customer’s shoes and pinpoint how your offer solves their problems? How do you tailor your message for the different channels and platforms?
Innovate UK EDGE and Cambridge digital…
Artificial Intelligence (AI) is changing the future of all industries, but findings published today by intellectual property firm, Marks & Clerk, reveal the medical technology (medtech) sector is surging ahead. The number of AI-based patent applications filed by the sector has almost quadrupled since 2018 to 2771 medtech publications in 2022. But most strikingly, as a standalone sector, the year-on-year percentage growth in the number of AI applications filed repeatedly surpassed that of overall AI between 2014 and 2021.
Breaking the findings down by subsector, the report reveals the…
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024
Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer
Conference call and webcast today at 8 a.m. ET
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Sep. 11, 2023-- Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today…